Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

[1]  C. Lepage,et al.  Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study , 2020, British Journal of Cancer.

[2]  K. Chok,et al.  Colorectal liver metastases: An update on multidisciplinary approach , 2019, World journal of hepatology.

[3]  M. Wagner,et al.  Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer , 2019, European Radiology.

[4]  Hyun S Kim,et al.  Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. , 2017, Surgical oncology.

[5]  V. Gebski,et al.  First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.

[6]  J. Meyerhardt,et al.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.

[7]  T. Gruenberger,et al.  PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  Robert C. G. Martin,et al.  Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy , 2016, Journal of surgical oncology.

[9]  T. Crocenzi,et al.  Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis , 2015, Cancer.

[10]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[11]  G. Fasola,et al.  Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials , 2015, Oncotarget.

[12]  T. Gruenberger,et al.  Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[14]  M. D'Angelica,et al.  Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab , 2014, Annals of Surgical Oncology.

[15]  J. Kleijnen,et al.  Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. , 2013, The Cochrane database of systematic reviews.

[16]  E. Van Cutsem,et al.  The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2012, The oncologist.

[17]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[18]  C. Scoggins,et al.  Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial , 2012, Journal of Gastrointestinal Surgery.

[19]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[20]  T. Hickish,et al.  A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  K. Gauvreau,et al.  Balloon Angioplasty and Stenting of Branch Pulmonary Arteries: Adverse Events and Procedural Characteristics Results of a Multi-Institutional Registry , 2011, Circulation. Cardiovascular interventions.

[22]  R. Martin,et al.  Toxicity of Irinotecan-Eluting Beads in the Treatment of Hepatic Malignancies: Results of a Multi-Institutional Registry , 2010, CardioVascular and Interventional Radiology.

[23]  L. Schwartz,et al.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Petrowsky,et al.  Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.

[26]  K. Syrigos,et al.  FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.

[27]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[28]  J. Pignon,et al.  Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases , 2003, The British journal of surgery.

[29]  U. Neumann,et al.  Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. , 2018, European journal of cancer.

[30]  J. Shindoh,et al.  Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  J. Weitz,et al.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.

[32]  A. Altendorf-Hofmann,et al.  A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. , 2003, Surgical oncology clinics of North America.

[33]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.